/PRNewswire/ The nuclear medicine industry is poised for significant growth in the near future, driven by the increasing incidence of cancer and chronic.
The radiopharmaceuticals developer Ariceum Therapeutics has bagged $24.9m (€22.8m) in a Series A extension round. Adding to a $27.4m (€25m) Series A closing last year, the Series A winnings for the German startup now total $52.3m (€47.8m).
During the forecast period, the Peptide Receptor Radionuclide Therapy (PRRT) Market is expected to grow at a strong CAGR of 7.2%. The market is currently worth US$ 552.08 million in 2022 and is expected to grow to US$ 1,106.50 million by 2032.This Peptide Receptor Radionuclide Therapy market study offers a comprehen.
Form PRE 14A Mirion Technologies, streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.